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Abstract:  Although  the  etiological  agent  of  Lyme  disease  has  been  known  since  1980s,  diagnosis  of  Lyme  disease  is  still  a
controversial topic because of the wide range of clinical manifestations and the limited diagnostic tools available to assess Borrelia in
humans.
The most used diagnostic tool for Lyme disease is currently serology, but also Polymerase chain reaction (PCR) and other methods
are often used to prove Borrelia infection in different patients’ specimens. The present article deals with most of the diagnostic tools
used in clinical practice for Lyme disease detection in human samples. Direct and indirect specific methods for Borrelia infection
detection will be discussed.
The most recent peer reviewed publications as well as original results from our study and information provided by companies’ web
sites have been analyzed to compile this review article.
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1. BACKGROUND
Although the etiological agent of Lyme disease has been known since 1980s, diagnosis of Lyme disease is still a
controversial topic [1]. The medical community is divided into two groups: the first one recognizes that Lyme disease is
associated with certain objective clinical manifestations supported by laboratory evidence of infection with Borrelia
burgdorferi  sensu  lato,  while  the  second  one  believes  that  Lyme  disease  patients  may  also  present  with  aspecific
symptoms without  laboratory evidence in  case  of  occult  infections  [1,  2].  Except  in  cases  with  the  pathognomonic
clinical manifestation of erythema migrans, the diagnosis of Lyme borreliosis usually requires confirmation by means
of a microbiological diagnostic assay [3]. Although the most informative tool for Borrelia detection is direct culture
isolation from blood or other body tissues, this approach is unsuitable for diagnosis and its use is confined to particular
situations. Indirect methods for Borrelia infection are thus preferred, and the main diagnostic tool for Lyme disease is
nowadays serology, which is the only one approved by the FDA (Food and Drug Administration). Detection of Borrelia
by  culture  isolation  and  nucleic  acid  techniques  is  confined  to  special  situations,  such  as  to  clarify  clinically  and
serologically ambiguous findings [3]. Recently, CE-IVD (European Community marked –in vitro Diagnostic Medical
Devices) tests for Borrelia  detection by PCR in clinical specimens have been produced [4 - 10], but none has been
approved  by  the  FDA.  In  the  following  sections  both  serologic  and  PCR techniques  for  Borrelia  detection  will  be
discussed.
Over the last decade non-specific tests have also been investigated for Lyme disease diagnosis; among them, CD57
cell count [11 - 13] and chemokine 13 level in cerebrospinal fluids [14 - 16] have been proposed with controversial
results. It is not the aim of this study to report on aspecific detection methods, therefore those types of analyses will not
be discussed hereafter.
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2. DIRECT DETECTION OF BORRELIA
A variety of laboratory techniques have been developed for direct detection of B. burgdorferi  sensu lato. Those
assays provide evidence for the presence of intact spirochetes or spirochete components such as DNA or protein in tick
vectors, reservoir hosts, or patients.
Four  different  approaches  have  been  used  in  the  clinical  laboratory:  microscope-based  assays,  detection  of
B. burgdorferi-specific proteins or nucleic acids, and culture [17].
2.1. Culture
Borrelia burgdorferi sensu lato can be cultivated from various tissues and body fluids in modified Kelly-Pettenkofer
medium (MKP), Barbour-Stoenner-Kelly II (BSK-II) medium, and commercially available BSK-H medium [3, 18]. The
yield of Borrelia culture from clinical samples is usually low with a higher rate of positivity from skin biopsy compared
to  blood  and  CSF  cultures  [18].  Borrelia  cultivation  and  isolation  is  a  time-consuming  and  demanding  procedure.
Successful  cultivation  can  take  up  to  12  weeks  [18].  In  addition,  preparation  of  culture  media  is  demanding  and
expensive. Nonetheless, cultivation is the golden standard to prove the presence of active infection by Borrelia. Slow
growth along with  low clinical  sensitivity  [17,  19]  do  not  make it  a  diagnostic  tool  for  Lyme disease,  and for  this
specific reason it will not be deeply considered in the present article.
2.2. Microscopy
Microscopic  detection  of  Borrelia  burgdorferi  sensu  lato  has  not  been  frequently  used  in  clinical  practice  for
confirmation of Lyme disease, mostly due to the sparseness of organisms in clinical samples [17]. Warthin-Starry stain,
which  consists  of  silver  impregnation  of  microorganisms,  was  the  oldest  method  used  to  search  for  Borrelia  in
histologic  preparations  in  the  1990s,  but  recently  only  two  publications  have  reported  on  the  use  of  this  stain  for
Borrelia  detection  [20,  21].  Among  microscopic  techniques  focus  floating  microscopy  (FFM),  a  modified
immunohistochemical  technique  that  combines  several  strategies  to  detect  minuscule  organisms  in  tissue  sections,
appears to be the most promising one for direct  Borrelia  detection,  because it  can be successfully applied on fresh
material, nitrogen-frozen material, and paraffin-embedded tissues, in many cases on blocks older than 30 years [22].
Focus-floating  microscopy  has  been  recently  proposed  as  the  possible  golden  standard  for  detecting  cutaneous
borreliosis [22]. Not only a polyclonal antibody to Borrelia, a vivid chromogen (3-amino-9-ethylcarbazole) and the
purposeful omission of counterstaining are necessary, but the technique also requires the histologist's patience [23]. By
meticulously examining the entire slide horizontally and vertically, Eisendle et al. [22] have been able to find organisms
with 98% sensitivity in classic examples of cutaneous borreliosis [22]. Since its first appearance in 2007 [22], FFM has
been  applied  to  several  studies  [21,  24  -  35],  enabling  detection  of  Borrelia  and  allowing  that  a  number  of
dermatological conditions, such as morphea and lichen sclerosus et atrophicus, could be attributed to Lyme Borreliosis
[28]. Unfortunately, although FFM is promising and helpful to prove Borrelia infection in cutaneous atypical lesions,
only a few centers have adopted this technique.
2.3. PCR
Direct  detection  of  Borrelia  in  clinical  specimens  is  typically  accomplished  by  PCR.  Advantages  of  PCR  are
sensitivity,  simplicity and speed [36].  A huge amount  of  articles  have been published reporting on the use of  PCR
assays for Borrelia detection in human specimens, but large comparative studies aimed to identify the best PCR method
are still lacking [3]. PCR assays differ in terms of target (borrelia sequence targeted by primers), PCR approach (nested
PCR, real time PCR, PCR followed by hybridization…) as well as type of samples (blood, biopsies, cerebrospinal fluid,
synovial fluid…) [37, 38]. Different types of PCR protocols could be applied for Borrelia detection, namely nested
PCR, PCR followed by hybridization, realtime PCR, the latter both in qualitative as well as quantitative setting [37, 38].
Several and different protocols, mostly in house, are in use in most laboratories. Differences in protocols also rely on
the type of samples and extraction procedures together with the broad range of clinical manifestations of Lyme disease.
Different methods could be used to extract DNA and they could have different yields. Moreover, DNA extracts could
be contaminated by PCR inhibitory substances due to poor extraction procedures [37]. Because of Borrelia paucity in
biological liquids and tissues the diagnostic sensitivity of PCR was found to be low when using low volumes of sample
material [3, 37]. As reported by Nolte PCR assays to detect Borrelia from CSF, synovial fluids or urines need large
volumes for extraction in order to increase the sensitivity of the method [37]. Low and transient spirochetemia and high
spirochoetes’ tropism for tissues (joints, heart,  meninges) may account for negative PCR results in blood and other
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biological fluids [38]. While PCR is highly sensitive for detection of B. burgdorferi sensu lato DNA in skin biopsy
samples, such testing for patients with Lyme disease involving systems other than skin, has in general low sensitivity,
with the exception of patients with Lyme arthritis [17]. PCR protocols for Borrelia detection have been developed by
targeting plasmid as well as borrelial chromosome. The most frequent target for plasmid borrelial DNA is OspA which
in  some  cases  have  also  been  used  for  Borrelia  genotyping  [36,  39  -  43].  Among  chromosomal  targets  the  most
frequently assessed in PCR assays are flagellin [43 - 47] and 66 kDa protein [41, 44, 48, 49] which were historically the
first targets analyzed by PCR and most recently the gene encoding the Borrelia 16S rRNA [36, 43, 48 - 50]. As some
plasmids may be present in more than a copy per Borrelia cell a plasmid target based PCR could be more sensitive. The
“target imbalance” in Borrelia assays could be one of the multiple issues affecting Borrelia detection by PCR [37].
Overall, standardization is the major concern with respect to PCR for Borrelia detection.
PCR detection of Borrelia DNA does not enable to distinguish between dead or living microorganisms, because it is
a  poor  indicator  of  the  viability  of  the  bacteria  [51].  To  this  regard,  quantitative  analysis  of  flagellin  B  mRNA of
Borrelia has been shown to correlate well with the culture results in Lyme disease, thus demonstrating the bacterial
viability [51]. Although RNA analyses for Borrelia could be a surrogate biomarker for Borrelia active infection it is
laborious and not suitable for routine analyses [37].
Recently,  several  CE-IVD  PCR  assays  have  been  developed  for  Borrelia  detection,  among  them:  the
EliGene®Borrelia  kit  (Elisabeth  Pharmacon  group,  Czech  Republic  and  UK);  the  Borrelia  burgdorferi  PCR  kit
(GeneProofa.s,  Czech  Republic),  the  real  time  PCR Borrelia  burgdorferi  sensu  lato  (Dynex,  Czech  Republic),  the
Borrelia burgdorferi s.l. kit (Biorn Diagnostics GmbH, Germany), the Borrelia Burgdorferi kit (Clonit S.r.l. , Italy), the
BactoReal®Borrelia Burgdorferi sensu lato (Ingenetix, Austria) and the Diarella Borrelia real time PCR Kit (Gerbion,
Germany) [4 - 10]. Most of them are qualitative real time PCR tests, multiplexing both an internal host control (human
housekeeping  gene) and  the  specific Borrelia target.  Detection  of  DNA of Borrelia species  pathogenic  to human
(B. afzelii, B. garinii, B. burgdorferi sensu stricto) has been guaranteed by amplifying flagellin gene [5 - 7], but also
OspA [9]. Those commercial kits could be used for blood, additionally tests could be applied to cerebrospinal fluid and
urine [4 -  6,  9,  10],  to ticks [4,  10] or  ticks’  suspension [6].  Sensitivities  of  those tests  are highly variable and not
conventionally described. Overall those commercial assays could have an impact on the reproducibility of PCR assays
for Borrelia detection only because they decrease the variability in the reagent preparations and primer design. To this
regard,  the  use  of  commercial  kits  represents  a  sort  of  harmonization  in  the  assay  preparation  rather  than
standardization. There are no scientific publications comparing the performance of those commercial products with
respect to serology, cultivation and in house PCR protocols in Lyme disease patients and controls. Clinical usefulness
and added value to routine of those commercial assays should be confirmed/assessed by large validation studies with
internal and external quality controls.
Overall, the scenario of PCR analyses for Lyme disease confirmation is wide and having reliable, reproducible tool
standardization is of paramount importance in all the phases of the PCR process, starting from sample selection (e.g.,
type of sample and the required volume to be processed) as well as the pre-analytical phases such as the extraction
procedures.
3. INDIRECT METHODS- SEROLOGY
Antibodies against Borrelia species are slow to develop, with IgM generally not being detectable for the first 1-2
weeks from the infection and IgG often not emerging for 4-6 weeks [52]. Moreover, there is evidence that some patients
with solitary erythema migrans (EM) as their only manifestation may never seroconvert [52], particularly in Europe
[53].
In Lyme disease the rate of seropositivity seems to correlate with the duration of symptoms before diagnosis [54]
and duration of treatment not only at presentation, but also during follow-up, indicating that early antibiotic treatment
may abrogate the development of seropositivity [52]. There is great variability in the specific antigens recognized by
individual sera and the extent to which serum antibodies recognize homologous proteins from other pathogenic Borrelia
species or even from heterologous strains of the same species [52, 55].
Both  IgM  and  IgG  Borrelia-specific  antibodies  may  persist  for  years  in  some  patients  [1],  which  makes  it
impossible to distinguish between past and newly acquired infections based on seropositivity alone [52]. Seroprevalence
indeed is of particular interest in endemic areas, showing in some European regions a gender and age trend [13, 56, 57].
In  Europe  [58],  United  States  [59]  and  Canada  a  two  tier  testing  serology  is  recommended  for  borreliosis
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assessment[1,  2,  60].  The  first  tier  consists  of  a  sensitive  initial  serological  test  or  tests  that  detect  class-specific
antibodies  (IgM  and  IgG,  either  together  or  separately).  First-tier  tests  are  enzyme  immunoassays  (EIAs)  such  as
ELISAs or, rarely today, indirect immunofluorescence assays (IFAs) as they require a skilled microscopist and cannot
be scored objectively. If the result of first-tier testing is negative, the serum is not tested further. If the result is positive
or indeterminate (a value that is sometimes called ‘borderline’), a second step should be performed [60]. The second tier
determines the antigens recognized by the antibodies detected in the first step using separate IgG and IgM immunoblots.
General limitations in serological tests for Lyme borreliosis are related to detectability of antibodies, to differences
in Borrelia genospecies and to the clinical spectra of the Lyme disease. It is well known indeed that two-tiered testing is
insensitive in acute erythema migrans and may be negative in early neuroborreliosis [1, 2, 52, 60].
General drawbacks for two tier approaches are that the two-step procedure is complex, technically demanding and
costly. Besides the technical aspects of the serological tests,  Perronne [2] has reported on several other factors that
could lead to seronegativity in confirmed cases of Lyme disease: among such factors are sequestration of antibodies in
immune complexes, different species and subspecies of Borrelia distributed worldwide, as well as coinfections with
other pathogens transmitted by the same vector.
Taken  those  observations  it  is  manifest  that  new  or  better  standardized  immunological  methods  are  needed  to
support the diagnosis of Lyme disease.
3.1. ELISA
Most commonly in ELISA, antigen mixtures composed of whole-cell sonicates of B. burgdorferi sensu lato are used
as the source of antigen for the the individual or in combination detection of IgG, IgM, or IgA antibodies. Usually those
sonicates  are  derived from strain  B31 [2],  a  specific  strain  of  Borrelia  burgdorferi  sensu stricto,  which is  the  only
organism established to cause Lyme disease in North America [60]. Since in Europe and Asia Lyme disease also results
from  infection  by  Borrelia  garinii  or  Borrelia  afzelii,  as  well  as  by  the  recently  described  Borrelia  spielmanii  in
Europe; diagnostic tests using antigens from B. burgdorferi sensu stricto will not necessarily perform well for infections
carried by other genospecies, although some do [60].
The  Vmp-like  sequence expressed (VlsE)  protein is a surface-exposed  lipoprotein encoded  by a linear plasmid of
B. burgdorferi B31 and it has been found to be highly immunogenic [17]. In the last decade, an ELISA using only a
single  synthetic  peptide  derived  from the  VlsE sequence  (IR6 or  C6 peptide)  as  the  source  of  antigen  has  become
commercially available and is quite often used in the first step of the serological analyses. Both the single C6 peptide
and whole VlsE assays have been approved as alternatives to whole-cell ELISAs as first-tier tests [60]. In addition, the
Immunetics C6 test (Immunetics Inc, MA, USA) has recently been evaluated as an assay that could be used in place of
both  steps  of  two-tiered  testing,  that  is,  as  a  simple  ‘stand-alone’  test  [60].  C6-  and  VlsE-based  assays  have  the
additional feature  of detecting  antibodies to  Eurasian  genospecies of Borrelia (i.e. B. gariniiand B. azfelii) as well as
B. burgdorferi sensu stricto [60]. Moreover, in a multiplex bead based assay for the detection of serum antibodies to
Borrelia  burgdorferi  sensu lato  it  has  recently  been shown that  VlsE IgG had the highest  diagnostic  value even in
patients with neuroborreliosis [61].
3.2. Immunoblots
Regarding immunoblots,  recommendations have been published by Centers  for  Disease Control  and Prevention
(CDC)  on  the  number  and  types  of  IgM  and  IgG  bands  in  order  to  consider  immunoblot  results  as  positive  [59].
However,  those rules  could be applied in  the US,  but  not  to  patients  infected in  Europe since immune response of
European patients is restricted to a narrower spectrum of Borrelia proteins, compared with that shown by American
patients [3].
Consequently, the existence of at least 3 pathogenic species requires species-specific interpretation rules [52].
Traditional  blots  are  hard  to  standardize,  as  they  are  only  semi-quantitative  and  reading  them  involves  often
subjective judgment about the significance of weak bands [60].
4. OUR EXPERIENCE
As  an  explicative  example  of  the  assumption  that  both  PCR  analyses  on  DNA  and  serology  do  not  allow
distinguishing between active and inactive Borrelia, here we report our (unpublished) data referred to serological and
PCR  analysis  of  healthy  volunteers  living  in  an  endemic  area.  All  the  participants  have  lived  in  villages  of  the
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transborder rural area between Italy and Slovenia and all of them reported having been bitten by ticks during their life.
All the participants in the study completed a questionnaire designed by the author of the presented study, and had both
serologic tests performed using immunoenzymatic test VlsE ELISA, by which the level of Borrelia burgdorferi IgM
and IgG class antibodies were determined in blood serum as well as two PCR analyses on blood extracts targeting a
fragment of flagellin gene and 66 kDa protein [44]. Blood and data were collected over May 2005. Fifty-two people
participated in this survey (median age 47 years), 31 of them were males and 21 females. Of those, 8 participants (5
males and 3 females) had had Lyme disease in the past. Among the requested information, participants reported the date
of their last tick’s bite, the therapy followed for concurrent chronic diseases, their job and if they had taken antibiotics
in the month before blood and data collection. Results and participants’ characteristics are reported in (Table 1). Overall
there are no differences in the antibody profiles between volunteers with previous Lyme disease or without. Both IgG
and IgM positivity and detection of Borrelia by PCR were not related to previous antibiotic treatment (p=1.0 for both)
as well as to concomitant chronic disease (p=1.0). IgG and IgM resulted simultaneously positive only in one participant,
a 67-year-old man who didn’t have Lyme disease previously. The only volunteer who had positive borrelia detection by
PCR (flagellin) was a 26-year-old man who reported Lyme disease (erythema migrans) 1 month before. In that person
IgG and IgM profiles were negative. All volunteers with positive IgG or IgM underwent dermatological examination
(PIC Interreg IIIA Italy-Slovenia 2000-2006 Project  No: AAFVG332366).  None of the seropositive volunteers had
signs of Lyme disease.
Table 1. Data on participants.
With previous Lyme disease (8) Without previous Lyme disease (44) p
Gender
Female
Male
5
3
18
26
0.9
IgG positive 4 11 0.2
IgM positive 1 7 0.6
PCR flagellin positive 1 0 0.2
PCR 66 kDa positive 0 0 1.0
Job
Clerical or educational workers
Retirees
Students
3
3
2
26
11
6
0.5
Overall both IgG and IgM positivity, as well as PCR, were not associated with any of the requested information
although IgG positivity tends to prefer older volunteers (p=0.08). IgG positivity did not result significantly different
among jobs, but IgM (p=0.04) was detected in 0 out 29 workers, in 1 out of 8 students and 3 out of 14 pensioners.
Our data agree with the scientific community [1, 60] regarding the usefulness of both PCR and serologic exams for
Borrelia detection in healthy people.
CONCLUSION
As a general consensus diagnostic investigation for Lyme disease should be restricted only to those people who
show signs and/or symptoms of Lyme disease. In endemic area serologic positivity could be a quite a frequent event
because of the exposition to Borrelia. Diagnostic tests are of clinical value only if they are used properly in patients
with objective signs of Lyme disease and with a history of potential exposure to infected vector ticks [60].
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